SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
A halin yanzu ana bincikar shi a cikin gwaji mai mahimmanci na Mataki na 2, CART-ddBCMA shine maganin T-cell na Arcellx wanda ke amfani da sabon abin ɗaure roba na kamfanin, D-Domain. Kite da Arcellx za su ci gaba tare da tallata kadarar CART-ddBCMA a Amurka, kuma Kite za ta tallata samfurin a wajen Amurka.
CAR T-Cell far yana daga cikin hanyoyin magance wasu nau'ikan cututtukan daji na jini. Akwai fiye da 750 da ke gudana gwaji na asibiti in CAR T-Cell far a China a halin yanzu. Marasa lafiya waɗanda ke son yin rajista za su iya tuntuɓar su Faxar Cancer Layin taimakon marasa lafiya akan WhatsApp + 91 96 1588 1588 ko imel zuwa info@cancerfax.com.
Game da Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory Multi myeloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic ciwo, initiated in the fourth quarter of 2022.
Game da Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Game da Kimiyyar Gilead
Gileyad Sciences, Inc. kamfani ne na biopharmaceutical wanda ya bi kuma ya sami ci gaba a fannin likitanci fiye da shekaru talatin, tare da burin ƙirƙirar duniya mafi koshin lafiya ga duk mutane. Kamfanin ya himmatu wajen haɓaka sabbin magunguna don rigakafi da magance cututtukan da ke barazana ga rayuwa, gami da HIV, hepatitis viral da kansa. Gileyad tana aiki a cikin ƙasashe sama da 35 a duk duniya, tare da hedkwata a Foster City, California. Kimiyyar Gileyad ta sami Kite a cikin 2017.
